Pasar al contenido principal

DIANAS EN EL SISTEMA ENDOCANNABINOIDE PARA EL DESARROLLO DE TERAPIAS FRENTE A LA NEURODEGENERACION: ENFASIS EN LA ELA Y OTRAS ENFERMEDADES NEURODEGENERATIVAS

SAF2015-68580-C2-1-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

  • Martínez-González, Loreto
  • Rodríguez-Cueto, Carmen
  • Cabezudo, Diego
  • Bartolomé Robledo, Fernando
  • Andrés-Benito, Pol
  • Ferrer, Isidro
  • Gil, Carmen
  • Martín-Requero, Ángeles
  • Fernández-Ruiz, Javier
  • Martínez Gil, Ana
  • De Lago, E.
12 p.-6 fig.-2 tab., Pathogenesis of amyotrophic lateral sclerosis (ALS), a devastating disease where no treatment exists, involves the compartmentalization of the nuclear protein TDP-43 (TAR DNA-binding protein 43) in the cytoplasm which is promoted by its aberrant phosphorylation and others posttranslational modifications. Recently, it was reported that CK-1delta (protein casein kinase-1delta) is able to phosphorylate TDP-43. Here, the preclinical efficacy of a benzothiazole-based CK-1delta inhibitor IGS-2.7, both in a TDP-43 (A315T) transgenic mouse and in a human cell-based model of ALS, is shown. Treatment with IGS-2.7 produces a significant preservation of motor neurons in the anterior horn at lumbar level, a decrease in both astroglial and microglial reactivity in this area, and in TDP-43 phosphorylation in spinal cord samples. Furthermore, the recovery of TDP-43 homeostasis (phosphorylation and localization) in a human-based cell model from ALS patients after treatment with IGS-2.7 is also reported. Moreover, we have shown a trend to increase in CK-1delta mRNA in spinal cord and significantly in frontal cortex of sALS cases. All these data show for the first time the in vivo modulation of TDP-43 toxicity by CK-1delta inhibition with IGS-2.7, which may explain the benefits in the preservation of spinal motor neurons and point to the relevance of CK-1delta inhibitors in a future disease-modifying treatment for ALS., This work was supported by MINECO (grant SAF2015-68580-C2-1-R to E.d.L., J.F.R., and C.R.C., SAF2016-76693-R to A.M. and CTQ2015-66313-R to A.M.R.),CIBERNED (CB06/05/0089 to C.R.C., J.F.R. and E.d.L.and CB18/05/00040 to A.M.R. and A.M.), Madrid Community (grant B2017/BMD3813 ELA-Madrid) and EU structural funds (FSE and FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

  • Espadas Villanueva, Isabel
  • Keifman, Ettel
  • Palomo-Garo, Cristina
  • Burgaz, S.
  • García, C.
  • Fernández-Ruiz, Javier
  • Moratalla, Rosario
The antioxidant and CB receptor agonist properties of Δ-tetrahydrocannabivarin (Δ-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti-dyskinetic potential of Δ-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated after inducing dyskinesia by repeated administration of L-DOPA (i.p. at 10 mg/kg) in a genetic model of dopaminergic deficiency, Pitx3 mutant mice, which serves as a useful model for testing anti-dyskinetic agents. The daily treatment of these mice with L-DOPA for two weeks progressively increased the time spent in abnormal involuntary movements (AIMs) and elevated their horizontal and vertical activities (as measured in a computer-aided actimeter), signs that reflected the dyskinetic state of these mice. Interestingly, when combined with L-DOPA from the first injection, Δ-THCV delayed the appearance of all these signs and decreased their intensity, with a reduction in the levels of FosB protein and the histone pAcH3 (measured by immunohistochemistry), which had previously been found to be elevated in the basal ganglia in L-DOPA-induced dyskinesia. In addition to the anti-dyskinetic effects of Δ-THCV when administered at the onset of L-DOPA treatment, Δ-THCV was also effective in attenuating the intensity of dyskinesia when administered for three consecutive days once these signs were already present (two weeks after the onset of L-DOPA treatment). In summary, our data support the anti-dyskinetic potential of Δ-THCV, both to delay the occurrence and to attenuate the magnitude of dyskinetic signs. Although further studies are clearly required to determine the clinical significance of these data in humans, the results nevertheless situate Δ-THCV in a promising position for developing a cannabinoid-based therapy for patients with PD., This work was supported by grants from CIBERNED (CB06/05/0055 (RM), PI2018/01-3 (JF-R) and CB06/05/0089 (JF-R)), MINEICO (SAF2016-78207-R and PCIN-2015-098 (RM), and SAF2015-68580-C2-1-R to JF-R), Instituto de Salud Carlos III (PNSD2016I033) (RM), the Ramón Areces Foundation (172275) (RM), and GW Research Ltd., UK (JF-R). Funding was also provided by the EMHE “Enhancing Mobility between Latin American and Caribbean countries and Europe”- a CSIC program, to Ettel Keifman. Sonia Burgaz is a predoctoral fellow supported by the Complutense University-Predoctoral Programme. These agencies had no further role in study design, collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis

  • Fernández-Trapero, María
  • Coates, Joan R.
  • Rodríguez Cueto, Carmen Aurora
  • Lago Femia, Eva De
  • Pérez Díaz, Carmen
  • Fernández Ruiz, José Javier
  • Espejo Porras, Francisco
Targeting of the CB2 receptor results in neuroprotection in the SOD1G93A mutant mouse model of amyotrophic lateral sclerosis (ALS). The neuroprotective effects of CB2 receptors are facilitated by their upregulation in the spinal cord of the mutant mice. Here, we investigated whether similar CB2 receptor upregulation, as well as parallel changes in other endocannabinoid elements, is evident in the spinal cord of dogs with degenerative myelopathy (DM), caused by mutations in the superoxide dismutase 1 gene (SOD1). We used well-characterized post-mortem spinal cords from unaffected and DM-affected dogs. Tissues were used first to confirm the loss of motor neurons using Nissl staining, which was accompanied by glial reactivity (elevated GFAP and Iba-1 immunoreactivity). Next, we investigated possible differences in the expression of endocannabinoid genes measured by qPCR between DM-affected and control dogs. We found no changes in expression of the CB1 receptor (confirmed with CB1 receptor immunostaining) or NAPE-PLD, DAGL, FAAH and MAGL enzymes. In contrast, CB2 receptor levels were significantly elevated in DM-affected dogs determined by qPCR and western blotting, which was confirmed in the grey matter using CB2 receptor immunostaining. Using double-labelling immunofluorescence, CB2 receptor immunolabelling colocalized with GFAP but not Iba-1, indicating upregulation of CB2 receptors on astrocytes in DM-affected dogs. Our results demonstrate a marked upregulation of CB2 receptors in the spinal cord in canine DM, which is concentrated in activated astrocytes. Such receptors could be used as a potential target to enhance the neuroprotective effects exerted by these glial cells.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

  • Rodríguez Cueto, Carmen Aurora
  • Hernández-Gálvez, Mariluz
  • Hillard, Cecilia
  • Maciel, Patricia
  • García-García, Luis
  • Valdeolivas, Sara
  • Pozo García, Miguel Ángel
  • Ramos Atance, José Antonio
  • Gómez Ruiz, María Sagrario
  • Fernández Ruiz, José Javier
  • García García, Luis
Spinocerebellar ataxia type-3 (SCA-3) is a rare disease but it is the most frequent type within the autosomal dominant inherited ataxias. The disease lacks an effective treatment to alleviate major symptoms and to modify disease progression. Our recent findings that endocannabinoid receptors and enzymes are significantly altered in the post-mortem cerebellum of patients affected by autosomal-dominant hereditary ataxias suggest that targeting the endocannabinoid signaling system may be a promising therapeutic option. Our goal was to investigate the status of the endocannabinoid signaling system in a transgenic mouse model of SCA-3, in the two CNS structures most affected in this disease - cerebellum and brainstem. These animals exhibited progressive motor incoordination, imbalance, abnormal gait, muscle weakness, and dystonia, in parallel to reduced in vivo brain glucose metabolism, deterioration of specific neuron subsets located in the dentate nucleus and pontine nuclei, small changes in microglial morphology, and reduction in glial glutamate transporters. Concerning the endocannabinoid signaling, our data indicated no changes in CB2 receptors. By contrast, CB1 receptors increased in the Purkinje cell layer, in particular in terminals of basket cells, but they were reduced in the dentate nucleus. We also measured the levels of endocannabinoid lipids and found reductions in anandamide and oleoylethanolamide in the brainstem. These changes correlated with an increase in the FAAH enzyme in the brainstem, which also occurred in some cerebellar areas, whereas other endocannabinoid-related enzymes were not altered. Collectively, our results in SCA-3 mutant mice confirm a possible dysregulation in the endocannabinoid system in the most important brain structures affected in this type of ataxia, suggesting that a pharmacological manipulation addressed to correct these changes could be a promising option in SCA-3.
Docta Complutense
Publicación Artículo científico (JournalArticle)

New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking

  • Ragusa, Giulio
  • Gómez Cañas, María
  • Morales, Paula
  • Pazos, María
  • Rodríguez Cueto, Carmen Aurora
  • Asproni, Battistina
  • Cichero, Elena
  • Fossa, Paola
  • Pinna, Gerard
  • Jagerovic, Nadine
  • Fernández Ruiz, José Javier
  • Murineddu, Gabriele
In the last few years, cannabinoid type-2 receptor (CB2R) selective ligands have shown a great potential as novel therapeutic drugs in several diseases. With the aim of discovering new selective cannabinoid ligands, a series of pyridazinone-4-carboxamides was designed and synthesized, and the new derivatives tested for their affinity toward the hCB1R and hCB2R. The 6-(4-chloro-3-methylphenyl)-2-(4-fluorobenzyl)-N-(cis-4-methylcyclohexyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide (9) displayed high CB2-affinity (KiCB2 = 2.0 ± 0.81 nM) and a notable selectivity (KiCB1/KiCB2 > 2000). In addition, 9 and other active new synthesized entities have demonstrated to behave as CB2R inverse agonists in [35S]-GTPγS binding assay. ADME predictions of the newly synthesized CB2R ligands suggest a favourable pharmacokinetic profile. Docking studies disclosed the specific pattern of interactions of these derivatives. Our results support that pyridazinone-4-carboxamides represent a new promising scaffold for the development of potent and selective CB2R ligands.